Cytosurge

Cytosurge is a private, commercial-stage company providing a unique technology platform and services for single-cell analysis and engineering. Its flagship FluidFM technology, originating from ETH Zurich, uses nanoscale fluidic force microscopy probes to perform cytoplasmic biopsies (Live-seq) and precise injections (e.g., for CRISPR) on living cells, enabling temporal studies of cell state transitions. The company operates a dual business model, offering both the FluidFM OMNIUM instrument for research labs and a CellEDIT service for custom cell line development, primarily targeting the cell therapy and synthetic biology markets to overcome challenges in hard-to-transfect cells and complex genetic edits.

FluidFM (Fluidic Force Microscopy): A patented platform combining atomic force microscopy with nanofluidics. It uses hollow cantilevers as nanosyringes to perform precise, minimally invasive intracellular injections and cytoplasmic extractions (biopsies) on individual living cells while maintaining high viability.

Cytosurge occupies a unique niche with its direct physical manipulation capability. In intracellular delivery, it competes with electroporation systems (e.g., Lonza, MaxCyte) and viral vectors, but offers superior precision and viability for single cells. In single-cell analysis, it competes with high-throughput but destructive droplet-based sequencing (10x Genomics) by enabling longitudinal study of the same cell, a capability with few direct competitors.